Advertisement

Digestive Diseases and Sciences

, Volume 51, Issue 11, pp 2045–2047 | Cite as

The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy

  • Lori A. Coburn
  • Paul E. Wise
  • David A. SchwartzEmail author
Original Article

The use of immunosuppressive medications during pregnancy in patients with Crohn's disease is controversial. However, most clinicians would agree that both the unborn baby and the mother will do better if the mother's inflammatory bowel disease (IBD) can be controlled. Studies have shown that patients with active Crohn's disease are more likely to experience preterm labor and have babies that are small for gestational age [1]. Currently, the most potent agent approved for Crohn's disease is infliximab. This is a chimeric anti–tumor necrosis factor-alpha (TNF-α) antibody. Recently, adalimumab (Humira), a fully humanized anti–TNF-α antibody, was approved for the treatment of rheumatoid arthritis (RA) [2, 3, 4, 5]. Preliminary studies have demonstrated efficacy in patients with Crohn's disease, including those who have had a reaction to or lost their response to infliximab because of the development of antibodies to the murine component of this agent [6, 7]. The safety of adalimumab in...

Keywords

Inflammatory Bowel Disease Infliximab Adalimumab Budesonide Weekly Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN (1998) Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 93:2426–2430PubMedCrossRefGoogle Scholar
  2. 2.
    Rau R (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(suppl 2):ii70–73Google Scholar
  3. 3.
    Weinblatt ME, Keystone EC, Furst DE, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45PubMedCrossRefGoogle Scholar
  4. 4.
    Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65:753–759PubMedCrossRefGoogle Scholar
  5. 5.
    Weisman MH, Moreland LW, Furst DE, et al. (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700–1721PubMedCrossRefGoogle Scholar
  6. 6.
    Sandborn WJ, Hanauer S, Loftus EV Jr, et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99:1984–1989PubMedCrossRefGoogle Scholar
  7. 7.
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75–79PubMedCrossRefGoogle Scholar
  8. 8.
    Mahadevan U, Kane S, Sandborn WJ, et al. (2005) Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21:733–738PubMedCrossRefGoogle Scholar
  9. 9.
    Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99:2385–2392PubMedCrossRefGoogle Scholar
  10. 10.
    Treacy G (2000) Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 19:226–228PubMedCrossRefGoogle Scholar
  11. 11.
    Hanauer S, Lukas M, MacIntosh D, Rutgeerts P, Sandborn WJ, Pollack P (2004) A randomized, double-blind, placebo-controlled trial of the human anti-TNF- alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 27:A332CrossRefGoogle Scholar
  12. 12.
    Sandborn WJ, Hanauer S, Lukas M, et al. (2005) Induction and maintenance of clinical response in subjects with Crohn's disease treated during a 6-month open-label period with fully humanized anti-TNF alpha monoclonal antibody adalimumab. Gastroenterology 128:A-111Google Scholar
  13. 13.
    Baidoo L, Lichtenstein GR (2005) What next after infliximab? Am J Gastroenterol 100:80–83PubMedCrossRefGoogle Scholar
  14. 14.
    Youdim A, Vasiliauskas EA, Targan SR, et al. (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10:333–338PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Lori A. Coburn
    • 1
  • Paul E. Wise
    • 1
  • David A. Schwartz
    • 2
    Email author
  1. 1.Inflammatory Bowel Disease CenterVanderbilt University Medical CenterNashvilleUSA
  2. 2.Inflammatory Bowel Disease Center; Division of GastroenterologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations